CorMedix

CRMD

Market cap $803M

CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.

CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.

- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant -

CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.

CorMedix is commercializing DefenCath, the only FDA-approved antimicrobial catheter-lock solution, with strong clinical results and rapid adoption in dialysis clinics. Medicare's TDAPA policy ensures full reimbursement for outpatient treatments, supporting near-term revenue as clinic penetration expands and inpatient rollout begins. Q2 2025 financials show $39.7M net revenue and $19.8M net income, with robust liquidity and growing contracts, including a major Large Dialysis Organization contributing significantly to sales.

CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.

CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.

CorMedix Inc. (NASDAQ:CRMD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Joseph Todisco - CEO & Director Conference Call Participants Ross Cohen Presentation Ross Cohen Okay. So thank you all for joining.

After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The completion of this financing is expected to provide the company with sufficient capital through the planned approval of a Niyad PMA in the second half of 2026 SAN MATEO, Calif. , Sept. 8, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has entered into securities purchase agreements with CorMedix Inc. and certain institutional investors for the sale and issuance of shares of common stock and pre-funded warrants in lieu of shares to purchase common stock in a private placement for total potential proceeds of up to $29 million.